This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Discussing AI use in drug discovery and development
Ticker(s): IBBWho's the expert?
Institution: Equum Medical- IQVIA
- Board-certified physician in Pulmonary and Critical Care Medicine with over 14 years’ experience in patient care and drug development research.
- He has served as Principal Investigator in clinical research in the academic setting and at the site level, and founded and directed a clinical research site network in Southern California successfully managing the execution of Phase 2 to Phase 4 clinical trials in a myriad of medical, vaccine, and device indications for 5 years before joining the CRO industry.
- Therapeutic expertise indications include bronchiectasis, NTM chest infections, pulmonary fibrosis, chronic cough, Alpha-1-Antitrypsin Deficiency, COPD, Cystic Fibrosis as well as critical care indications such as ARDS, COVID, CHF, and post cardiothoracic surgery indications
Interview GoalThis interview will focus on how AI is impacting drug discovery/development now and outlook for the future, emerging AI leaders among biotech/pharma co.'s, AI vendors, other groups (like CROs) using AI in drug discovery/development
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
